While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Biopharma layoff rounds reported this May hit an all-time high, with 29 reductions in force (RIFs) occurring—the most of any month reported over the last four years that Fierce Biotech has spent ...

For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of reads. The relentless nature of industry layoffs has garnered the most ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Biotech firms use AI in trials to target patients more ...

The field of biotechnology has always transformed cutting-edge science into life-changing medicines, but today that transformation is happening at a staggering pace. New discoveries are faster, ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

A hand holds up a tamper-safe orange bottle filled with oblong white pills against a red-tinted background of Chinese yuan. As China’s biopharmaceutical industry churns out more innovative molecules, ...